secwatch.observer — SEC 8-K summary
======================================

Issuer:     CalciMedica, Inc. (CALC)
CIK:        0001534133
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001193125-25-044830
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CalciMedica reports 62.7% relative mortality reduction with Auxora in AKI subset of CARDEA trial
--------------------------------------------------------------------------------

- In patients with AKI (eGFR ≤60) plus respiratory failure, Auxora reduced day-30 mortality by 62.7% vs placebo; 17.4% vs 46.7% died.
- Absolute mortality reduction of 29.3% in AKI subset; full study showed 56.3% relative reduction (p=0.017) with 9.9% absolute reduction.
- Preclinical and biomarker data supporting CRAC channel inhibition in AKI were also presented.
- Ongoing Phase 2 KOURAGE trial in Stage 2/3 AKI with hypoxemic respiratory failure is expected to read out in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534133/000119312525044830/0001193125-25-044830-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534133/000119312525044830/d824505d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-044830

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer